[go: up one dir, main page]

AR029451A1 - Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia - Google Patents

Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Info

Publication number
AR029451A1
AR029451A1 ARP000102365A ARP000102365A AR029451A1 AR 029451 A1 AR029451 A1 AR 029451A1 AR P000102365 A ARP000102365 A AR P000102365A AR P000102365 A ARP000102365 A AR P000102365A AR 029451 A1 AR029451 A1 AR 029451A1
Authority
AR
Argentina
Prior art keywords
therapy
breast cancer
product
composition
human beings
Prior art date
Application number
ARP000102365A
Other languages
English (en)
Inventor
Salle Enrico Di
Tiziana Zaccheo
Michele Tedeschi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR029451A1 publication Critical patent/AR029451A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto para su uso en la terapia para el cáncer de mamas en seres humanos, que contiene un agente antineoplásico y un inhibidor de aromatasa, en cantidades efectivas para producir un efecto antitumoral superaditivo, para su administracion en forma separada, simultánea o secuencial en la terapia para el cáncer de mamas en seres humanos.
ARP000102365A 1999-05-18 2000-05-17 Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia AR029451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911582.6A GB9911582D0 (en) 1999-05-18 1999-05-18 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Publications (1)

Publication Number Publication Date
AR029451A1 true AR029451A1 (es) 2003-07-02

Family

ID=10853700

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102365A AR029451A1 (es) 1999-05-18 2000-05-17 Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Country Status (6)

Country Link
EP (1) EP1178831A1 (es)
JP (1) JP2003512301A (es)
AR (1) AR029451A1 (es)
AU (1) AU3820700A (es)
GB (1) GB9911582D0 (es)
WO (1) WO2000069467A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8986501A (en) * 2000-09-08 2002-03-22 Pharmacia & Upjohn Spa Exemestane as chemopreventing agent
MXPA03004195A (es) * 2000-11-16 2003-09-22 Upjohn Co Terapia combinada para los trastornos dependientes de estrogenos.
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
MXPA03010401A (es) * 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
EP2648721B1 (de) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Kombinationen von aromatase inhibitoren und antioxidanzien
CN113633644A (zh) 2014-10-22 2021-11-12 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Also Published As

Publication number Publication date
EP1178831A1 (en) 2002-02-13
AU3820700A (en) 2000-12-05
WO2000069467A1 (en) 2000-11-23
JP2003512301A (ja) 2003-04-02
GB9911582D0 (en) 1999-07-21

Similar Documents

Publication Publication Date Title
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
AR028764A1 (es) Boquilla para la aplicacion de un producto cosmetico, su procedimiento de fabricacion y dispositivo de acondicionamiento y de aplicacion que utiliza dicha boquilla
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
AR027355A1 (es) Acidos tiazolidincarboxilicos
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
MY138883A (en) Use of asiatic acid for treatment of cencer
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
SV2001000212A (es) Una combinacion de agentes antineoplasticos que comprenden acetildinalina y paclitaxel y/o carboplatina y juego que la comprende
PT1220676E (pt) Prevencao do cancro colorrectal

Legal Events

Date Code Title Description
FB Suspension of granting procedure